Hepatology Communications Publishes Data From Mirum's LIVMARLI In Primary Sclerosing Cholangitis
Portfolio Pulse from Happy Mohamed
Mirum Pharmaceuticals announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, and efficacy of LIVMARLI in patients with primary sclerosing cholangitis (PSC). The study provided proof-of-concept for the Phase 2b VISTAS study evaluating volixibat, an IBAT inhibitor, in patients with PSC.
May 18, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals' CAMEO study data on LIVMARLI shows potential for treating primary sclerosing cholangitis, supporting the Phase 2b VISTAS study evaluating volixibat.
The positive data from the CAMEO study on LIVMARLI provides proof-of-concept for the Phase 2b VISTAS study evaluating volixibat, an IBAT inhibitor, in patients with PSC. This progress in the development of a potential treatment for PSC is likely to have a positive short-term impact on Mirum Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100